Neurology: In patients with new coronary disease, different inflammatory neurological diseases have different inflammatory cytokine profiles

 

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent of COVID-19 , mainly manifested by fever, myalgia, diarrhea and respiratory diseases.
As of September 2020, there have been more than 30 million cases and 1 million deaths worldwide.
SARS-CoV-2 infection is also associated with a variety of central nervous system (CNS) syndromes, including headaches, encephalopathy, and inflammatory neurological diseases, such as encephalitis, meningoencephalitis, acute disseminated encephalomyelitis (ADEM) and Acute myelitis.

COVID-19 infection

The pathogenesis of these neurological manifestations may include: neuronal damage caused by immune- mediated processes, excessive inflammation caused by cytokine release syndrome, post-infection or para-infectious inflammation, and even secondary events related to the impact of systemic diseases , Such as sepsis, high fever, hypoxia, hypercoagulability and critical illness.

immunity

Although SARS-CoV-2 RNA can be detected in brain tissue, it is still unclear whether its mechanism and events are secondary to SARS-CoV-2's neuroinvasion (neuroinvasion) or the influence of peripheral inflammatory cytokines .

However, it is still unclear whether the mechanism and event are secondary to the neuroinvasion of SARS-CoV-2 or the influence of inflammatory cytokines from the periphery, but it is still unclear whether the mechanism and event are secondary to SARS-CoV-2 Neuroinvasion, or the influence of inflammatory cytokines from the periphery

Otávio M.
Espíndola of Brazil's National Institute of Infectology and others evaluated the levels of several cytokines in the cerebrospinal fluid (CSF) and serum of COVID-19 patients.

They found thatbased on the analysis of cerebrospinal fluid and serum samples of 48 people, patients with new coronary disease can have obvious neurological manifestations.
Inflammatory nervous system diseases and increased levels of interleukin (IL)-2, IL-4, IL-6, IL-10, IL-12, chemokine ligand 8 (CXCL8) and CXCL10 in cerebrospinal fluid (CSF) related.

 Based on the analysis of cerebrospinal fluid and serum samples of 48 people, patients with new coronary disease may have obvious neurological manifestations.
Inflammatory nervous system diseases and increased levels of interleukin (IL)-2, IL-4, IL-6, IL-10, IL-12, chemokine ligand 8 (CXCL8) and CXCL10 in cerebrospinal fluid (CSF) related.
Based on the analysis of cerebrospinal fluid and serum samples of 48 people, patients with new coronary disease may have obvious neurological manifestations.
Inflammatory nervous system diseases and increased levels of interleukin (IL)-2, IL-4, IL-6, IL-10, IL-12, chemokine ligand 8 (CXCL8) and CXCL10 in cerebrospinal fluid (CSF) related.

On the contrary, encephalopathy is related to high serum levels of IL-6, CXCL8 and active tumor growth factor β1.

On the contrary, encephalopathy is related to high serum levels of IL-6, CXCL8 and active tumor growth factor β1.
On the contrary, encephalopathy is related to high serum levels of IL-6, CXCL8 and active tumor growth factor β1.

These results show that the central nervous system inflammatory syndrome of COVID-19 can appear in the early stage, as a side infection process without obvious system involvement, and there may be no evidence that the new coronavirus directly invades the brain.
At the same time, encephalopathy is mainly affected by peripheral events, including inflammatory cytokines.

In addition, patients with inflammatory and non-inflammatory neurological diseases associated with COVID-19 have different cytokine profiles in the CNS and the periphery.

Original source:
wiley.

com/doi/full/10.
1002/ana.

wiley.
com/doi/full/10.
1002/ana.
26041" target="_blank" rel="noopener">Espíndola, OM, Gomes, YC, Brandão, CO, Torres, RC, Siqueira, M.
, Soares, CN, .

Leave a message here